Molecular Pharmacology Program

The Steven Larson Lab

Research

Steven M. Larson, MD

My laboratory’s primary expertise is in molecular imaging, targeted radio diagnosis, and therapy using small molecules and monoclonal antibodies.

Currently, I am corresponding primary investigator of Memorial Sloan Ketterings’s In Vivo Cellular and Molecular Imaging Center (ICMIC) and coleader, with Ingo Mellinghoff and Charles Sawyers, of Research Project 4, studying molecular imaging correlates and biology of activation of the AR-axis in castrate-resistant prostate cancer. This project builds on extensive prior imaging collaborations with prostate cancer specialists Howard Scher, Michael Morris, and Peter Scardino and has led to the development of molecular imaging approaches to androgen receptor (AR) imaging as well as several novel radioantibodies that image downstream effectors of AR signaling.

View Lab Overview

Research Projects

Featured News

In Brief

A Precision Strike to Treat Prostate Cancer

Tuesday, April 24, 2018

An antibody that targets a prostate cell protein shows potential for designing safer, more effective prostate cancer therapies.

In the Lab

More Precise Imaging of Prostate Cancer Could Give Insight into Drug Effectiveness

Thursday, December 29, 2016

An antibody that targets a protein specific to prostate cells can be used to image prostate cancer more clearly and indicate how well drugs are working.

In the Clinic

Bone Scan Index May Help Determine Response to Prostate Cancer Treatment

Friday, January 13, 2012

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

View All Featured News

Publications

Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29.

Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.PMID: 25143071

Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26.

Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK. Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight. 2016 May 5;1(6). pii: e87030.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med. 2016 Nov 30;8(367):367ra167. PMID:27903863

View All Publications

People

Steven M. Larson, MD

Nuclear medicine physician Steven Larson focuses on molecular imaging in animals and humans using high-resolution diagnostic instruments, such as positron emission tomography, and single photon emission tomography.
MD, University of Washington School of Medicine (Seattle)

larsons@mskcc.org: Email Address
646-888-3592: Office Phone
View physician profile: Physician profile

Members

Daniela Burnes Vargas
Research Technician

Jorge Carrasquillo, MD — Jorge Carrasquillo
Attending/Member PI

Chris Chandler

Sarah Cheal — Sarah M. Cheal
Senior Research Scientist

Kevin Fisher
Senior Administrative Assistant

Neeta Pandit-Taskar
Attending, Molecular Imaging and Therapy Service, Department of Radiology; Member, Memorial Hospital; Professor, Dept. of Radiology, Weill Cornell; Clinical Director, Center for Radioimmunotargeted Imaging and Theranostics of the Ludwig Center for Cancer

Darren Veach
Assistant Attending Chemist

Lilly (Jiong) Wu
Senior Research Technician

Pat Zanzonico, PhD — Pat Zanzonico
Attending Physicist and Co-Director, Animal Imaging

Lab Alumni

Julio Arevalo-Perez, MD, PhD — Julio Arevalo-Perez
Radiology Fellow

Kishore Gangangari
Graduate Research Assistant with Hunter College CUNY

Ahmad Shariftabrizi

Graduate Medical Education

Hans David Ulmert, MD, PhD — Hans David Ulmert
Sr. Research Scientist

Gregor Forster

Research Fellow

Bipin Mehta

Assistant Laboratory Member

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Postdoctoral Fellowship

Apply now

Get in Touch

larsons@mskcc.org

Lab Head Email
646-888-3592

Office Phone
646-888-2220

Lab Phone
646-422-0408

Lab Fax

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Steven M. Larson discloses the following relationships and financial interests:

Cardinal Health
Provision of Services (uncompensated)
Elucida Oncology
Intellectual Property Rights; Ownership / Equity Interests
Fonds de recherche du Quebec
Provision of Services

Samus Therapeutics LLC
Intellectual Property Rights
Voreyda
Ownership / Equity Interests
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures